CANbridge Pharmaceuticals Inc. (1228.HK) HKSE

Currency In HKD

CANbridge Pharmaceuticals Inc.

Address

Timeloit

Beijing,

China

Phone

86 10 8414 8018

Website

https://www.canbridgepharma.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

December 10, 2021

Key Executives

Name	Title	Pay	Year Born
Qun Xue	Founder, Chairman of the Board, Chief Executive Officer & Member of Strategic Advisory Board	3.91M	1970
Chris Chen	Senior Vice President of Human Resources	0	N/A
Joe Shen	Chief Operating Officer	0	N/A
Lillian Zhang	Senior Director & Head of Finance Operations and Controller	0	N/A
Rebecca Zhang	Chief Regulatory Advisor	0	N/A
Will Wang	Executive Director of Production	0	N/A
Qian Ma	Vice President, Company Secretary & General Counsel	0	N/A
Jeff Kou	Head of Clinical Operations and Senior Director of R&D Strategy & Portfolio Management	0	N/A
Jason West	Head of Global Gene Therapy Research	0	N/A
Gerald F. Cox	Chief Development Strategist & Interim Chief Medical Officer	0	1959

Description

CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase, an enzyme replacement therapy for Hunter syndrome; NERLYNX (Neratinlib), a powerful, irreversible tyrosine kinase inhibitor targeting HER2-positive breast cancer; and Caphosol Mouth Rinse, used to alleviate temporary and persistent dry mouth and throat. Its robust development pipeline features several investigational therapies: CAN008, an artificially engineered antibody-like fully human fusion protein being developed for glioblastoma multiforme; CAN108, an orally administered reversible inhibitor of the ileal bile acid transporter, designed to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 for complement-mediated conditions; CAN103 and CAN104, both recombinant human enzyme replacement therapies (ERTs); CAN105, a bispecific antibody; and gene therapy programs CAN201 and CAN202, both utilizing adeno-associated virus (AAV) sL65 capsid technology. Established in 2012, CANbridge Pharmaceuticals Inc. is based in Beijing, China.